Tagrisso (osimertinib): Dosage and administration

23 Jul

Tagrisso (osimertinib): Dosage and administration

Check out the essential information about Dosage and Administration of Tagrisso (osimertinib) at MTO Pharma.

Non-Small Cell Lung Cancer

Indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.

Also indicated for metastatic EGFR T790M mutation positive NSCLC, as detected by an FDA approved test, in patients who have progressed on or after EGFR TKI therap 80 mg PO qDay; continue until disease progression or unacceptable toxicity.

Searching where to buy brand original Tagrisso 80 mg (osimertinib)? Order Tagrisso (osimertinib) right now in MTO Pharma online pharmacy. Click here to redirect to the product page.

Image result for viber whatsapp pngFor instant requiry and answers to your question contact us on Viber +380507552484 or on WhatsApp +380687225383

Dosage Modifications

Renal impairment

  • Mild-to-moderate (CrCl 15-89 mL/min): No dose adjustment required.
  • End-stage renal disease (ESRD): There is no recommended dose.

Hepatic impairment

  • Mild (total bilirubin ≤upper limit of normal (ULN) and AST >ULN or total bilirubin between 1-1.5x ULN and any AST) or moderate (total bilirubin between 1.5-3x ULN and any AST): No dose adjustment required
  • Severe: There is no recommended dose.

Pulmonary adverse effects

  • Interstitial lung disease/pneumonitis: Permanently discontinue.

Cardiac adverse effects

  • QTc interval >500 msec on at least 2 separate ECGs: Withhold until QTc interval <481 msec or recovery to baseline if baseline QTc is ≥481 msec, then resume at 40 mg dose.
  • QTc interval prolongation with signs/symptoms of life-threatening arrhythmia: Permanently discontinue.
  • Symptomatic CHF: Permanently discontinue.

Other adverse effects

  • Adverse reaction≥Grade 3: Withhold for up to 3 weeks.
  • If improvement to grade 0-2 within 3 weeks: Resume at 80 mg or 40 mg daily.
  • If no improvement within 3 weeks: Permanently discontinue.

Coadministration of CYP3A4 inducers

  • Strong CYP3A4 inducer: Avoid use; If coadministration is unavoidable, increase osimertinib dosage to 160 mg daily when coadministering with a strong CYP3A inducer; resume osimertinib at 80 mg 3 weeks after discontinuation of the strong CYP3A4 inducer.
  • Moderate and/or weak CYP3A inducers: No dose adjustments required.
  • Information on FDA-approved tests for the detection of EGFR mutations is available at http://www.fda.gov/companiondiagnostics

Geriatric Dosing and Indications

No overall differences in effectiveness were observed based on age

Exploratory analysis suggests a higher incidence of Grade 3 and 4 adverse reactions (13.4% versus 9.3%) and more frequent dose modifications for adverse reactions (13.4% versus 7.6%) in patients ≥65 years as compared to those <65 year.

Dosing Considerations

First-line treatment of metastatic EGFR-positive NSCLC: Confirm the presence of EGFR exon 19 deletions or exon 21 L858R mutations in tumor or plasma specimens.

Metastatic EGFR T790M mutation-positive NSCLC: Confirm the presence of T790M mutation in tumor specimens prior to initiating treatment.

Searching where to buy brand original Tagrisso 80 mg (osimertinib)? Order Tagrisso (osimertinib) right now in MTO Pharma online pharmacy. Click here to redirect to the product page.

Image result for viber whatsapp pngFor instant requiry and answers to your question contact us on Viber +380507552484 or on WhatsApp +380687225383

Leave a Reply

Your email address will not be published. Required fields are marked *